What to Expect When Johnson & Johnson Reports Tuesday Morning

By Chris Lange Updated Jan 11, 8:58PM EST · Published Jul 16, 10:25AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

What to Expect When Johnson & Johnson Reports Tuesday Morning — © Feverpitched / iStock

Johnson & Johnson (NYSE: JNJ) is set to report its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $2.07 in earnings per share (EPS) and $20.4 billion in revenue. In the same period of last year, the company said it had EPS of $1.83 and $18.84 billion in revenue.

In its most recent report, Johnson & Johnson guided EPS in the range of $8.00 to $8.20 and revenues between $81.0 billion and $81.8 billion for the full year. The consensus estimates are $8.13 in EPS on $81.51 billion in revenue.

Alex Gorsky, board chair and chief executive, commented in the past quarter:

We are pleased with the strong and consistent performance delivered by our colleagues around the world, demonstrated by our sales and EPS growth in the first quarter. Our Pharmaceutical business continues to deliver robust growth and we are pleased with the improvement in our Consumer business. In our Medical Devices businesses, we have areas of leadership and continue to make investments and portfolio choices to improve performance.

[nativounit]

Excluding Monday’s move, the stock had underperformed the broad markets, down about 10% year to date. Over the past 52 weeks, the stock was down about 4.5%.

Ahead of the earnings report a few analysts weighed in on the stock:

Jefferies has a Buy rating with a $145 price target.
Credit Suisse has a Buy rating and a $151 price target.
Goldman Sachs has a Neutral rating.
Sanford Bernstein has a Market Perform rating and a $129 target.
Citigroup has a Neutral rating with a $134 target price.
Wells Fargo has an Outperform rating with a $150 price target.

Shares of Johnson & Johnson were last seen down about 1% at $124.88, with a consensus analyst price target of $142.24 and a 52-week trading range of $118.62 to $148.32.

[recirclink id=477402]

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.